Sanofi has removed (PDF) a clutch of programs from its clinical pipeline, scratching out entries for its late-phase BTK inhibitor and phase 1 prospects linked to the multibillion-dollar takeovers ...

Less than two years later, Acelyrin raised $540 million in an IPO to bankroll late-phase trials of izokibep in multiple indications. The biotech subsequently soured on izokibep. Now, Acelyrin has ...